Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: CD as drug

March 31, 2026 CD as API / CD derivatives / Drug delivery / Pharma applications

Phosphorylated Beta-cyclodextrin as a New Bone-Targeting Drug Delivery System Could Change the Treatment of Osteoporosis and Other Bone Diseases

Researchers in Japan have developed a promising new drug delivery platform that not only carries medicines directly to bone, but

Continue reading

March 19, 2026 CD as API / CD derivatives / Pharma applications

Evaluation of the Potential Therapeutic Effects of HPβCD and SBEβCD in a Mouse Model of Acute Ulcerative Colitis

A Nanjing, China based research group designed a tailored investigation [1] based on a surprising previous study [2]. In they

Continue reading

March 16, 2026 CD as API / Pharma applications

HPαCD Therapy: A Breakthrough for Krabbe Disease Treatment

Several North-American Universities worked together to find hydroxzpropyl-alpha-cyclodextrin(HPaCD) for the treatment of Krabbe disease. The deficiency of β-galactosylceramidase causes a

Continue reading

February 19, 2026 CD as API / Drug delivery / Pharma applications

Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin

Previous studies have demonstrated that the solubility and biocompatibility of poorly water-soluble anti-cancer agents can be improved by complexation with

Continue reading

December 19, 2022 CD as API / Pharma applications

HPβ-CD as affordable antiviral to treat coronavirus infection

In a recent study posted to the bioRxiv* preprint server, researchers identified β-cyclodextrins (β-CDs) as a safe and cost-effective drug

Continue reading

May 4, 2022 CD as API / CD derivatives / Drug delivery / Pharma applications

Implementation of water-soluble cyclodextrin-based polymers in biomedical applications: how far are we?

Cyclodextrin-based polymers can be prepared starting from the naturally occurring monomers following green and low-cost procedures. They can be selectively

Continue reading

January 12, 2022 CD as API / Pharma applications

Cyclodextrin for treating lymphedema

A recent patent application of NATIONAL UNIVERSITY OF SINGAPORE claims for the treatment of lymphedema by using empty cyclodextrin (beta-cyclodextrin

Continue reading

October 15, 2021 Events

Statistics of registered participants at the CycloLab’s webinar on “Cyclodextrins as active ingredients in the 21st century”

The webinar was a great success with altogether 793 registered participants from 66 countries. The highest interest was shown by

Continue reading

October 12, 2021 CD as API / Drug delivery / Pharma applications

Versatile Nasal Application of Cyclodextrins: Excipients and/or Actives?

The use of CDs in nasal formulations allowed obtaining versatile drug delivery systems intended for local and systemic effects, as

Continue reading

October 4, 2021 CD as API / Drug delivery / Pharma applications

Cyclodextrin, beyond drug vector: When the administration matters

Cyclodextrin (CD) are classicaly know to be an excellent drug carrier although applications as active drug have been studied (orphan

Continue reading

Posts pagination

1 2 Next Posts»

Recent Posts

  • Cyclodextrin Produced In situ: Rethinking Oat Milk Design for Better Performance
  • Structural diversity of cyclodextrin metal-organic frameworks enables their diverse applications
  • Exploring Cyclodextrin-Based MOFs for Drug Delivery: Synthesis, Applications, and Future Perspectives
  • Sugammadex analog water soluble BCD polymer for peptide complexes
  • 2 nd International Conference on Biomedical Science and Engineering

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (26)
  • Analysis (64)
  • CD as API (343)
  • CD derivatives (404)
  • Cosmetics and toilettry (49)
  • Diagnosis (12)
  • Drug delivery (786)
  • E-ducation (63)
  • Environmental (133)
  • Events (233)
  • Food (221)
  • Gene delivery (20)
  • Household products (4)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (42)
  • Non-pharma applications (396)
  • Other industrial use (104)
  • Pharma applications (1,173)
  • Supramolecular systems (40)
  • Uncategorized (144)

Top Posts

  • Cyclodextrin Produced In situ: Rethinking Oat Milk Design for Better Performance
  • Structural diversity of cyclodextrin metal-organic frameworks enables their diverse applications
  • Cyclodextrin-based formulations for pediatric patients: pharmaceutical prospectives and toxicological evaluation
  • Lanosterol eye drops for cataract treatment
  • Practical Considerations about the Cyclodextrin Solubilities – A Quickstart Guide for Newbies
  • FDA Grants Approval to HPBCD-Enhanced Biologic: A 'Super-Originator' Formulation
  • Antiepileptic drug with betadex sulfobutyl ether sodium, Fycompa® injection approved in Japan
  • "Advances in Functional Materials" International Conference, 2021
  • Alterations in Proteostasis Mechanisms in Niemann–Pick Type C Disease
  • Aequus and reVision to Collaborate on Stargardt Disease Program using SBECD as active

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 3,791 other subscribers

Loading Comments...